A Phase I Study of Low Dose Subcutaneous Interleukin-2 (IL-2) For The Treatment of Ulcerative Colitis.

Trial Profile

A Phase I Study of Low Dose Subcutaneous Interleukin-2 (IL-2) For The Treatment of Ulcerative Colitis.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs Aldesleukin (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Jan 2017 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
    • 30 Jan 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
    • 18 Mar 2015 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top